Perpetual Ltd’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.5M Buy
2,407
+262
+12% +$178K 0.02% 193
2026
Q1
$1.66M Hold
2,145
0.03% 175
2025
Q4
$1.66M Buy
+2,145
New +$1.46M 0.02% 190
2024
Q4
Sell
-69,706
Closed -$73.3M 449
2024
Q3
$73.3M Sell
69,706
-3,819
-5% -$4.25M 0.79% 46
2024
Q2
$77.3M Sell
73,525
-11,254
-13% -$10.9M 0.84% 38
2024
Q1
$81.6M Sell
84,779
-15,440
-15% -$14.7M 0.8% 47
2023
Q4
$88M Sell
100,219
-6,335
-6% -$5.22M 0.91% 34
2023
Q3
$87.7M Sell
106,554
-7,883
-7% -$6.2M 0.91% 37
2023
Q2
$82.2M Sell
114,437
-7,226
-6% -$5.57M 0.71% 48
2023
Q1
$100M Buy
+121,663
New +$91.8M 0.86% 35
2020
Q3
$3.33M Sell
5,953
-906
-13% -$549K 0.24% 133
2020
Q2
$4.28M Buy
6,859
+313
+5% +$178K 0.4% 73
2020
Q1
$3.2M Buy
+6,546
New +$2.7M 0.45% 92
2017
Q3
Sell
-13,971
Closed -$6.86M 227
2017
Q2
$6.86M Hold
13,971
0.54% 59
2017
Q1
$5.27M Hold
13,971
0.52% 58
2016
Q4
$5.13M Buy
13,971
+2,514
+22% +$956K 0.78% 36
2016
Q3
$4.61M Buy
+11,457
New +$4.6M 0.38% 69

Other funds holding REGN

Perpetual Ltd's REGN Position: Q2 2026 in Review

Perpetual Ltd increased its Regeneron Pharmaceuticals (REGN) stake by 12% in Q2 2026, buying an estimated $178K and bringing the position to 2,407 shares worth $1.5M. The position accounts for 0.02% of the portfolio, ranked #193.

Perpetual Ltd first reported a position in REGN in Q3 2016 and has held it in 17 quarters since. The position peaked at $100M in Q1 2023. 419 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Perpetual Ltd held 2,407 shares of Regeneron Pharmaceuticals worth $1.5M as of Q2 2026.
  • Perpetual Ltd bought 262 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $178K.
  • Regeneron Pharmaceuticals made up 0.02% of Perpetual Ltd's portfolio in Q2 2026, its #193 holding.
  • Perpetual Ltd first reported a position in Regeneron Pharmaceuticals in Q3 2016 and has held it in 17 quarters since.
  • Perpetual Ltd's Regeneron Pharmaceuticals position peaked at $100M in Q1 2023.
  • 419 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Perpetual Ltd's 13F filing for Q2 2026, filed 15 Jul 2026.